Kalamazoo, MI, United States

ProNAi Therapeutics

pronai.com
Kalamazoo, MI, United States
SEARCH FILTERS
Time filter
Source Type

The report Strategic Trends in Private Equity and Venture Capital Funding for Healthcare provides a comprehensive analysis on emerging investment trends within the healthcare industry. Private equity (PE) and venture capital (VC) funds have been important participants in a wide range of industries for many decades - particularly the healthcare industry. Completed global healthcare private equity deal values exhibited a negative compound annual growth rate (CAGR) of 11.8% from 2010 to 2015, with 2010 recording a total of $33.9 billion, falling to $18.1 billion by 2015. In 2007, the total value of completed global healthcare Private Equity deals was USD 66.2Billion. This plummeted by 81% to USD 12.6 Billion in 2008. In 2010, the market showed signs of recovery when deal values reached an aggregate of USD 33.9 Billion, an increase of 170.3% from 2008. However, recent years have witnessed a steady decline, with 2015 and 2014 being the exception. Deal values exhibited a negative compound annual growth rate (CAGR) of 11.8% from 2010 to 2015, with 2015 recording a total of USD 18.1 Billion. Despite the recent uptick, 2015 values were nowhere near pre-crash levels. For example, PE deal values recorded totals of USD 53.6 Billion and USD 66.2 Billion in 2006 and 2007, respectively. The continued decline in R&D productivity is one of the most important challenges the healthcare industry is facing at a global level. Blockbuster therapies, for example, have become increasingly rare, and many drugs continue to face reimbursement challenges in key markets, resulting in declining revenues for companies. 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Overview of Private Equity and Venture Capital 2.2 The Significance of Private Equity and Venture Capital in the Healthcare Industry 2.2.1 The Venture-Backed Healthcare Innovation Model 2.2.2 Critical Factors to Consider when Selecting a Venture Capital Firm 2.2.3 What Are the Types of Private Equity Firms Operating in the Healthcare Industry? 3 Global Trends in Private Equity and Venture Capital Investments in the Healthcare Industry 3.1 Is R&D Productivity in Healthcare Still Declining? 3.2 What is Causing the Increase in the Cost of Bringing Medical Interventions to Market? 3.3 Global Healthcare Private Equity Deal Trends: Volume and Value, 2006-2015 3.4 Regional Healthcare Private Equity Deal Trends: Volume and Value, 2006-2015 3.5 Which Therapy Areas Are Receiving Noteworthy Private Equity Investment? 3.6 Top 10 Healthcare Private Equity Deals, 2015 3.7 Top 10 Healthcare Venture Capital Deals, 2015 3.8 Are New Companies in the Healthcare Industry Living in a Post-VC Era? 3.9 What are the Risks if Investments in the Healthcare Industry Decrease Significantly? 3.10 New Funding and Investment Models Emerging in the Healthcare Industry 3.10.1 The Role of Crowdfunding in Early-Stage Healthcare in the Post-VC Era 4 US Private Equity and Venture Capital Industry Dynamics 4.1 Immediate Aftermath of the 2008 Global Financial Crisis on the Value of Capital Commitments to Private Funds in the US 4.2 Venture Capital Fundraising Trends in the US: Volume and Value of Funds, 2006-2015 4.3 US Venture Capital Investment Trends 4.4 Is Biotechnology Still Playing Second Fiddle to the Software Sector? 4.5 Trends in Seed Stage VC Financing in the US by Volume and Value, 2015 4.6 US Venture-Backed Exits, Volume and Value, 2006-2015 4.7 US Venture-Backed Healthcare Acquisitions 2006-2015 5 Equity Offerings in the Healthcare Sector, Value and Volume, 2006-2015 5.1 US Venture-Backed Initial Public Offerings in Healthcare, 2006-2015 5.2 Company Profiles and Initial Public Offer Details 5.2.1 Axovant Sciences (Stock Symbol: AXON) 5.2.2 NantKwest (Stock Symbol: NK) 5.2.3 Adaptimmune Therapeutics (Stock Symbol: ADAP) 5.2.4 Spark Therapeutics (Stock Symbol: ONCE) 5.2.5 Aimmune Therapeutics (Stock Symbol: AIMT) 5.2.6 Blueprint Medicines (Stock Symbol: BPMC) 5.2.7 RegenxBio (Stock Symbol: RGNX) 5.2.8 ProNAi Therapeutics (Stock Symbol: DNAI) 5.2.9 Seres Therapeutics (Stock Symbol: MCRB) 5.2.10 Global Blood Therapeutics (Stock Symbol: GBT) 6 Private Equity Firms, Company Drill-Downs 6.1 TPG Capital 6.2 The Carlyle Group 6.3 Apax Partners 6.4 KKR & Co 6.5 Warburg Pincus 6.6 Bain Capital Private Equity 7 Venture Capital Firms, Company Drill-Downs 7.1 New Enterprise Associates 7.2 OrbiMed Advisors 7.3 Kleiner Perkins Caufield & Byers 7.4 Flagship Ventures 7.5 Third Rock Ventures 7.6 Versant Ventures 8 Future Outlook 8.1 What Factors will Drive Investment in Healthcare Industry in Coming Years? 8.2 Will New Financing Models Provide Sustainable Growth for Early-Stage Healthcare Companies? 8.3 Which Geographical Markets will Drive Investment in Healthcare in Foreseeable Future? 8.4 How will Venture Capital Firms React to Increasing Competition in Healthcare Sector? 9 Conclusions 10 Bibliography 11 Appendix Companies Mentioned - Adaptimmune Therapeutics - Aimmune Therapeutics - Apax Partners - Axovant Sciences - Bain Capital Private Equity - Blueprint Medicines - Flagship Ventures - Global Blood Therapeutics - KKR & Co - Kleiner Perkins Caufield & Byers - NantKwest - New Enterprise Associates - OrbiMed Advisors - ProNAi Therapeutics - RegenxBio - Seres Therapeutics - Spark Therapeutics - TPG Capital - The Carlyle Group - Third Rock Ventures - Versant Ventures - Warburg Pincus For more information about this report visit http://www.researchandmarkets.com/research/mcgznj/strategic_trends To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/strategic-trends-in-private-equity-and-venture-capital-funding-for-healthcare---research-and-markets-300443446.html


News Article | February 27, 2017
Site: globenewswire.com

Basel, Switzerland, February 27, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that its Board of Directors proposes Dr. Nicole Onetto for election as a non-executive member of the Board at its Annual General Meeting of Shareholders to be held on April 27, 2017. Domenico Scala, Chairman of Basilea's Board of Directors, said: "Basilea has successfully brought to market two hospital anti-infectives, the antifungal Cresemba and the antibiotic Zevtera/Mabelio. As we are also progressing toward important decision points in our oncology portfolio, the Board has decided to further strengthen its expertise in oncology. We are therefore very pleased that Dr. Onetto has agreed to be nominated to join our Board. She has a distinguished career with a wealth of experience operationally and strategically in developing and bringing novel and innovative oncology drugs to patients." Dr. Nicole Onetto, a French and Canadian citizen, currently serves as an independent consultant for oncology, drug development and translational research in Vancouver, Canada. Prior to that, from 2009 to 2016, she was Deputy Director & Chief Scientific Officer at the Ontario Institute for Cancer Research (OICR) in Toronto, Canada. From 2005-2009 she was Senior Vice President and Chief Medical Officer at ZymoGenetics Inc. Between 2002 and 2005, she served at OSI Pharmaceuticals, Inc., first as Executive Vice President-Oncology and then as Chief Medical Officer and Executive Vice President. Her career in the pharmaceutical industry also includes senior management positions at Bristol-Myers Squibb and Nexstar Pharmaceuticals, which was acquired by Gilead Sciences, Inc. She is currently on the board of ProNAi Therapeutics, a Vancouver-based oncology hematology company, and previously served for eleven years as a member of the board of ImmunoGen Inc. and a number of other public and private pharmaceutical companies in the oncology sector. Dr. Onetto obtained her MD from the University of Paris and holds a Master of Pharmacology from the University of Montréal. If Dr. Onetto is newly elected and all current Board members are re-elected, Basilea's Board of Directors will consist of seven members: Prof. Daniel Lew, Dr. Martin Nicklasson, Dr. Thomas M. Rinderknecht (current Vice-Chairman), Domenico Scala (current Chairman), Dr. Nicole Onetto, Steven D. Skolsky and Dr. Thomas Werner. Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products that address the medical problem of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com. This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For further information, please contact: This press release can be downloaded from www.basilea.com.


Patent
ProNAi Therapeutics | Date: 2014-07-10

The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition of oncogenes involved in cancers.


Patent
ProNAi Therapeutics | Date: 2013-11-05

The present invention relates to cancer therapies, compositions, and methods of using the same. In particular, the present invention provides methods of dosing and administration of cancer therapies comprising the administration of oligomers and liposome formulations of oligomers, wherein the cancer is mediated by the bcl-2 oncogene. In some aspects, the oligomers or liposome formulations of oligomers are administered in combination with one or more other therapeutic agents.


Patent
ProNAi Therapeutics and Novosom AG | Date: 2014-12-12

The invention relates to compositions and methods to inhibit gene expression. In particular, the invention provides DNAi oligonucleotides sequestered by amphoteric liposomes for the treatment of cancer.


Patent
ProNAi Therapeutics | Date: 2016-03-30

The invention relates to compositions and methods to inhibit gene expression. In particular, the invention provides co-therapies comprising oligonucleotides plus other therapies to treat cancer.


Patent
ProNAi Therapeutics | Date: 2012-03-23

The invention relates to compositions and methods to inhibit gene expression. In particular, the invention provides co-therapies comprising oligonucleotides plus other therapies to treat cancer.


Patent
ProNAi Therapeutics | Date: 2014-03-14

The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition genes implicated in many diseases.


The present invention relates to cancer therapies and methods of using the same. In particular, the present invention provides methods of monitoring and improving the administration of cancer therapies, wherein the cancer is mediated by the BCL2 oncogene, via markers of disease identification, disease progression, drug resistance, and/or treatment efficacy.


Patent
Novosom AG and ProNAi Therapeutics | Date: 2013-01-28

The invention relates to compositions and methods to inhibit gene expression. In particular, the invention provides DNAi oligonucleotides sequestered by amphoteric liposomes for the treatment of cancer.

Loading ProNAi Therapeutics collaborators
Loading ProNAi Therapeutics collaborators